"If immunotherapy eliminates most of the tumor before surgery, then we have sufficiently trained the immune system for an antitumor response, which minimizes the possibility of recurrence," said lead ...

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

Total neoadjuvant therapy demonstrates consistent real-world efficacy across regimens in patients with locally advanced ...

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

Presenters at the 2025 ASCO Annual Meeting shared how clinicians can optimize surgical outcomes for frail patients with locally advanced NSCLC.

AstraZeneca secures CDSCO approval to import Durvalumab for muscle-invasive bladder cancer treatment in India.

AstraZeneca receives CDSCO approval for Durvalumab, a new treatment for muscle-invasive bladder cancer in India. This marks a ...

Triple-negative breast cancer (TNBC) comprises 10–15% of all breast cancers. It is a very heterogeneous disease, ...

Participants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...

Neoadjuvant intralesional daromun significantly extended recurrence-free survival and lowered distant relapse risk in ...

Announcing a new article publication for BIO Integration journal. Imbalances in the intestinal microbiome are closely ...

Adding stereotactic ablative radiotherapy (SAbR) to neoadjuvant chemotherapy improves pathologic outcomes for patients ...